Collegium Pharmaceutical (COLL) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Collegium Pharmaceutical (COLL) do?
Collegium Pharmaceutical Inc (COLL) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Markets prescription pain therapies directly to healthcare providers across the United States. Sells pain management medications formulated with technology designed to deter abuse and misuse. It is worth $783.42M on the market and sold $816.06M over the last year.
- Market cap
- $783.42M
- P/E ratio
- 25.4×
- Annual sales
- $816.06M
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 17, 2026
Brands and businesses behind COLL
- Belbuca: Generates revenue as a buprenorphine buccal film prescribed to manage severe pain requiring daily opioid therapy.
- Xtampza ER: Generates sales as an abuse-deterrent extended-release oxycodone capsule prescribed for severe chronic pain.
- Nucynta: Brings in pharmaceutical revenue as tapentadol tablets prescribed for acute and severe chronic pain relief.
- Symproic: Produces revenue as an oral prescription tablet designed to treat opioid-induced constipation in adult patients.
COLL’s flags, in plain English
Each flag is a number from Collegium Pharmaceutical’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Cheap on Cash Flow
Priced at 2.3 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Wide Gross Margin
Gross margin of 59.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 20.3% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Debt Is Driving
Heavy debt, 407% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about COLL
How big is Collegium Pharmaceutical?
Collegium Pharmaceutical’s market cap is $783.42M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $816.06M: what customers paid the company over the last year, before any costs.
What is COLL’s P/E ratio?
COLL’s P/E ratio is 25.4×. Investors pay about 25.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with COLL?
Revenue depends heavily on a small portfolio of pain medications facing patent challenges and generic competition. That is one risk on Collegium Pharmaceutical’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Collegium Pharmaceutical’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. COLL’s filings on SEC.gov. The Margin Monkey is research, not advice.
